Study examines which IBD drugs are safer for seniors

NCT ID NCT07250815

Not yet recruiting Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This study looked at nearly 24,000 older adults (65+) with ulcerative colitis or Crohn's disease to see if certain advanced treatments lead to more infections. Researchers compared patients taking ENTYVIO, TNF-alpha inhibitors, or ustekinumab using Medicare claims data from 2016 to 2025. The goal was to understand the risk of serious and non-serious infections in this age group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If this study finds differences in infection rates, it could help doctors choose safer treatments for older patients with inflammatory bowel disease.
What could go wrong: This is an observational study using existing data, so it cannot prove cause and effect. Results may be influenced by unmeasured factors or differences in patient health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN'S DISEASE ULCERATIVE COLITIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Takeda Site

Cambridge, Massachusetts, 02142, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.